Biocon Limited (NSE:BIOCON)

Biocon Financials Overview

Financials in millions INR. Fiscal year is April - March.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Revenue Revenue Growth	173,211	169,270	152,617	147,557	111,742	81,840
Revenue Growth	9.83%	10.91%	3.43%	32.05%	36.54%	14.57%
Gross Profit Gross Profit Growth	105,980	102,664	92,441	91,735	69,617	50,111
Operating Income Operating Income Growth	16,830	16,943	15,431	17,834	15,643	11,583
Net Income Net Income Growth	4,953	3,856	10,133	10,225	4,627	6,484
Earnings Per Share EPS Growth	3.37	2.82	8.46	8.54	3.87	5.42
EPS Growth	4.95%	-66.67%	-0.94%	120.67%	-28.60%	-12.44%

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Biosimilars Biosimilars Growth	108,290	104,312	90,174	88,242	55,838	34,643
Generics Generics Growth	32,975	31,681	30,175	27,985	27,644	23,409
Services Services Growth	36,002	37,387	36,424	34,886	31,929	26,042
Inter-Segment Inter-Segment Growth	-4,056	-4,110	-4,156	-3,556	-	-
Total Total Growth	173,211	169,270	152,617	147,557	111,742	81,840

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Investments Cash & Investments Growth	38,831	38,831	45,651	25,740	37,263	29,649
Total Debt Total Debt Growth	154,341	154,341	183,620	162,767	180,188	51,468
Net Cash (Debt) Net Cash Growth	-115,510	-115,510	-137,969	-137,027	-142,925	-21,819
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share Net Cash Per Share Growth	-78.47	-84.40	-115.15	-114.49	-119.51	-18.24

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Cash Flow Operating Cash Flow Growth	-	19,940	40,612	29,539	18,525	11,766
Capital Expenditures CapEx Growth	-	-17,979	-21,366	-16,805	-15,960	-16,978
Free Cash Flow Free Cash Flow Growth	-	1,961	19,246	12,734	2,565	-5,212
Free Cash Flow Growth	-	-89.81%	51.14%	396.45%	-	-

Margins

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Gross Margin	61.19%	60.65%	60.57%	62.17%	62.30%	61.23%
Operating Margin	9.72%	10.01%	10.11%	12.09%	14.00%	14.15%
Pretax Margin	2.76%	2.65%	12.36%	10.34%	8.03%	12.01%
Profit Margin	2.86%	2.28%	6.64%	6.93%	4.14%	7.92%
FCF Margin	-	1.16%	12.61%	8.63%	2.30%	-6.37%

Dividends

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 22, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Dividend Per Share Dividend Per Share Growth	0.500	0.500	0.500	0.500	1.500	0.500
Dividend Per Share Growth	0%	0%	0%	-66.67%	200.00%	-
Dividend Yield	0.12%	0.14%	0.15%	0.19%	0.73%	0.15%

Valuation

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 22, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	123.42	151.47	40.36	30.85	53.21	61.56
Forward PE	81.16	61.80	56.28	34.10	21.39	35.74
P/FCF Ratio	343.19	297.84	21.25	24.77	95.98	-
PS Ratio	3.89	3.45	2.68	2.14	2.20	4.88

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 21, 2026

Data Sources Report a data error